Matthew Lee, MD, discusses the first clinical data for BG-C477, a CEACAM5-targeting ADC, in advanced NSCLC.
|Articles|August 19, 2013
Using Quality-Measures Data to Address Sleep-Wake Disturbances
At ONS Congress 2013, Janet Gordils-Perez, Carla Schaefer, and Jacquelyn Lauria from CINJ discuss evidence-based tools developed to support nursing assessment and effective interventions for patients with sleep-wake disturbances (abstract 120187).
Advertisement
At ONS Congress 2013, Janet Gordils-Perez, Carla Schaefer, and Jacquelyn Lauria from CINJ discuss evidence-based tools developed to support nursing assessment and effective interventions for patients with sleep-wake disturbances (abstract 120187).
Advertisement
Related to this article
Jan Kitajewski, PhD, explains how Notch inhibitors may sustain specialized tumor blood vessels that deliver immune cells and boost immuno-oncology.
In a phase 3 trial, the Breast Cancer Locator was noninferior to wire localization and lowered positive margin rates in nonpalpable breast cancer.
ASCENT-03 subgroup data show sacituzumab govitecan improved PFS vs chemotherapy across subgroups in untreated metastatic TNBC.
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Bispecific antibodies targeting PD-L1 showed activity across first-, second-, and later-line advanced neuroendocrine carcinoma in 3 trials presented at ESMO 2026.
Petosemtamab plus pembrolizumab cut the risk of death by 50% vs pembrolizumab alone in first-line recurrent or metastatic PD-L1–positive head and neck cancer.
"As we combine more treatments…they have overlapping toxicities, and they may have the ability to synergize in a negative way," said Dwight H. Owen, MBBCh, MS.
Advertisement
Advertisement
Trending on CancerNetwork
1
Prior Regimen Did Not Affect Daraxonrasib Benefit in Pretreated Pancreatic Cancer
2
Petosemtamab/Pembrolizumab Improves OS in First-Line PD-L1–Positive HNSCC
3
What Are the Top Takeaways for Neuroendocrine Carcinoma From 2026 ESMO?
4
Sacituzumab Govitecan PFS Benefit Holds Across Subgroups in Untreated mTNBC
5